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Case Study in Optimal Dosing in
Duodenal Ulcer
Karl E. Peace
Jiann-Ping Hsu College of Public Health, Georgia Southern University Statesboro
USA
1. Introduction
Duodenal ulcers occur in the duodenum – the upper portion of the small intestine as it
leaves the stomach. A duodenal ulcer is characterized by the presence of a well-demarcated
break in the mucosa that may extend into the muscularis propria [Thompson et al, 2010].
Cimetidine (C) was the first H2-Receptor Antagonist to receive regulatory approval (in the
late 1970s) for the treatment of duodenal ulcers. When it was being developed it was widely
held that duodenal ulcers were caused by excessive gastric acid production. In fact the
prevailing medical opinion was no acid, no ulcer. Sir James Black and colleagues at
SmithKline and French Laboratories are credited with the discovery of C. They discovered
that histamine released by the H2-receptor stimulated the production of gastric acid, and
that C by blocking the release of this histamine would suppress both normal and food
stimulated gastric acid secretion [Nayak & Ketteringham, 1986]. In a reduced acidic
environment, ulcers would be able to heal. The first C regimen approved for the treatment
of duodenal ulcers in the United Kingdom was 1000 mg per day, given as: 200 mg at
breakfast, lunch and dinner, and 400 mg at bed time, for up to 4 weeks. The first regimen
approved in the United States for this indication was 1200 mg per day, given as: 300 mg
q.i.d. for up to 4 weeks. Subsequently, other indications were obtained, and dosing regimens
modified; for example, 800 mg per day, given as 400 mg bid.
In the mid 1980's, based upon data from gastric acid anti-secretory studies at various doses
and frequencies of dosing, there was reason to believe that a single night time (hs) dose of
800 mg of C for up to 4 weeks would be the clinically optimal regimen for treating patients
with duodenal ulcers. A large, landmark, dose comparison clinical trial [Dickson et al, 1985;
Peace et al, 1985; Valenzuela et al, 1985; Young et al, 1989] was undertaken to confirm the
effectiveness of 800 C mg hs in the treatment of duodenal ulcers for up to four weeks. When
the author was first consulted by the project physician and regulatory affairs expert, the
clinical development plan consisted of two, randomized, double-blind, placebo controlled,
pivotal proof of efficacy trials with single nighttime dosing for four weeks:
Trial 1: 800 mg C hs vs. Placebo, and Trial 2: 1200 mg C hs vs. Placebo.
Each trial was to enroll 150 patients per treatment group, for a total of 600 patients. Onehundred-fifty patients per group would provide a power of 95% to detect a 20% difference
in cumulative four-week ulcer healing rates between the C and Placebo groups with a 1-
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sided, Type I error [Peace, 1991a] of 5%. Since conducting these trials would subject ½ the
patients to Placebo, the author recommended amalgamating the two trials into a single trial:
Trial 3: 1200 mg C hs vs. 800 mg C hs vs. 0 mg C hs (Placebo)
with 164 patients per treatment group, for a total of 492 patients. One-hundred sixty-four
patients per treatment group would provide a power of 95% to detect a difference of 20% in
four week ulcer healing rates between any two of the treatment groups with an experiment
wise Type I error of 5% (1.67% per each 1-sided, pair-wise comparison). Not only would this
trial require fewer patients and be less expensive to conduct, it would also provide a within
trial comparison between C doses, for dose discrimination.
Further savings could be realized by incorporating into the Trial #3 protocol, a planned
interim analysis after ½ the patients had been entered and completed. At the interim
analysis, the efficacy comparisons: 1200 mg C vs. Placebo, and 800 mg C vs. Placebo would
be tested. If both were statistically significant, then the entire study could be stopped – if
efficacy of the doses were the only objective. If comparing the doses of C was also of clinical
importance, then the Placebo arm could be stopped and the two C arms run to full
completion to assess dose discrimination. By conducting Trial #3 (instead of the two
separate trials) and incorporating the interim analysis, potential savings of up to 190
patients could be realized. Additional savings would be expected due to less time required
to conduct the trial [Peace, 1990, 1991b}.
The primary objective in conducting a clinical trial of C in the treatment of duodenal ulcers
with a single nighttime dose was to demonstrate that 800 mg C was clinically optimal. We
therefore added a 400 mg dose and replaced the 1200 mg dose with a 1600 mg dose (a twofold increase among consecutive doses) in the final trial protocol, which was IRB approved.

2. Materials and methods
2.1 Objective
Both primary and secondary efficacy objectives were identified in the final protocol. The
primary objective addressed ulcer healing. The secondary objective addressed upper
gastrointestinal (UGI) pain relief.
The primary objective was to confirm that C given as a single nighttime dose of 800 mg for
up to 4 weeks was clinically optimal in healing duodenal ulcers. Clinically optimal meant
that 800 mg C was effective (significantly superior to placebo), that 800 mg C was superior
to 400 mg C, and that 1600 mg C was not significantly superior to 800 mg C. Symbolically
the primary (note p subscript of H) objective derives from three null and alternative
hypotheses:
Hp01: Puh800 = Puh0 ,

Hp02: Puh800 = Puh400 ,

Hp03: Puh1600 = Puh800

Hpa1: Puh800 > Puh0 ,

Hpa2: Puh800 > Puh400 ,

Hpa3: Puh1600 ≠ Puh800 .

where Puh0, Puh400, Puh800 and Puh1600 represent the cumulative ulcer healing (uh) rates by week
4 in the Placebo, 400 mg C, 800 mg C and 1600 mg C treatment groups, respectively, under
single nighttime (hs) dosing. Specifically, Hpa1, Hpa2 and Hp03 comprised the primary study
objective.
Symbolically, the secondary (note s subscript of H) objective derives from the three null and
alternative hypotheses:
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Hs01: Ppr800 = Ppr0 ,

Hs02: Ppr800 = Ppr400 ,

Hs03: Ppr1600 = Ppr800

Hsa1: Ppr800 > Ppr0 ,

Hsa2: Ppr800 > Ppr400 ,

Hsa3: Ppr1600 ≠ Ppr800 .

where Ppr0, Ppr400, Ppr800 and Ppr1600 represent the UGI pain relief (pr) rates in the Placebo,
400 mg C, 800 mg C and 1600 mg C treatment groups, respectively, under single
nighttime (hs) dosing. Specifically, Hsa1, Hsa2 and Hs03 comprised the secondary study
objective.
Of the six possible pairwise comparisons among the 4 dose groups, only three comprised
the study objective. The other three: 1600 mg C versus 0 mg C, 1600 mg C versus 400 mg C,
and 400 mg C versus 0 mg C were not part of the study objective and thus did not exact a
Type I error penalty (i.e. the overall Type I error of 5% was ‘Bonferonnied’ across the three
pairwise comparisons comprising the study objective, and not across the 6 possible pairwise
comparisons).
2.2 Designing and planning the investigation
The trial was multicenter, stratified, randomized, double-blind and Placebo (0 mg C)
controlled. Neither patients, investigators nor their staff knew the identity of the C
regimens. As there had been reports [Korman et al, 1981; Korman et al, 1983; Lam & Koo,
1983; Barakat et al, 1984] of the influence of smoking on the healing of duodenal ulcers at the
time of protocol development, patients were stratified by smoking status within each center
prior to randomization to the treatment groups. Smoking strata were Light Smokers and
Heavy Smokers. Patients who smoked at most 9 cigarettes per day comprised the Light
Smoker stratum. Patients who smoked at least 10 cigarettes per day comprised the Heavy
Smoker stratum.
2.3 Blinded treatment groups
Blinded treatment group medication was packaged using the existing regulatory approved
400 mg C tablet. A 400 mg Placebo tablet was formulated identical to the 400 mg C tablet
except that it contained 0 mg C. Blinded trial medication for the four treatment groups was
packaged in blister packs for 4 weeks of nightly treatment as identified below:
0 mg C Group:
400 mg C Group:
800 mg C Group:
1600 mg C Group:

Four 400 mg Placebo tablets
One C 400 mg tablet + three 400 mg Placebo tablets
Two C 400 mg tablets + two 400 mg Placebo tablets
Four C 400 mg tablets.

2.4 Sample size determination
The trial was designed to recruit and enter enough patients to complete one-hundred sixtyfour (164) per treatment group, for a total of 656 patients. One-hundred sixty-four patients
per treatment group would provide a power of 95% to detect a difference of 20% in
cumulative four week ulcer healing rates between any two of the treatment groups with an
experiment wise Type I error rate of 5% (1.67% per each 1-sided, pair-wise comparison).
This number was inflated to account for a 15% drop out rate. A cumulative four week
healing rate of 45% among Placebo treated patients [de Craen et al, 1999] in previous trials
was used in the sample size determination.
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2.5 Entry requirements and assessment schedule
Patients were required at entry to have an endoscopically confirmed duodenal ulcer of size
at least 0.3 cm, and either daytime or nighttime UGI pain. After providing informed consent,
at the preliminary examination or baseline visit, patients provided a history (including prior
use of medications, particularly anti-ulcer ones or antacids), underwent a physical
examination, had vital signs measured, provided blood and urine samples for clinical
laboratory assessments, in addition to having UGI pain assessed and undergoing
endoscopy. Patients were also instructed how to use a daily diary to record the severity of
daytime or nighttime UGI pain, as well as to record any adverse experience or concomitant
medication use. Diaries and trial medication were dispensed and the patients instructed to
return at weeks 1, 2 and 4 of the treatment period for follow-up endoscopy, UGI pain
assessment and assessment of other clinical parameters. Antacids were provided to patients
for relief of severe pain during the first six days/ nights of therapy only, and were limited to
4 tablets per day of low acid-neutralizing capacity. Table 1 summarizes clinical assessments
made throughout the trial.
Follow-up endoscopic evaluation was carried out following strict time windows (Table 1) at
week 1 (Days 7-8), week 2 (Days 13-15) and week 4 (Days 26-30). Patients whose ulcers were
healed at any follow-up endoscopy were considered trial completers and received no
further treatment or endoscopic assessment.
Clinical
Parameter

Preliminary
Examination1

History

Y

Physical Exam

Y

Vital Signs

Y

Week 1 (Days 7-8)

Week 2 (Days 13-15)

Week 4 (Days 26-30)

Y

Y

Y

Y

Y

Y

Adv. Events
Con. Meds

Y

Y

Y

Y

Endoscopy

Y

Y

Y

Y

Pain Assessment

Y

Y

Y

Y

Clin. Labs.

Y

Y

1

Y

After providing Informed Consent

Table 1. Clinical Evaluation Schedule
2.6 Primary and secondary endpoints
The primary efficacy data was ulcer healing at week 1, 2 or 4. Ulcer healing was defined as
complete reepithelization of the ulcer crater (normal or hyperemic mucosa), documented by
endoscopy. The primary efficacy endpoint was cumulative ulcer healing at week 4 (healed
at week 1 or week 2 or week 4).
Secondary efficacy data were the severity ratings of daytime and nighttime UGI pain
recorded by the patient on the daily diary card. The severity of daytime pain was recorded
just prior to going to sleep at night. The severity of nighttime pain was recorded upon
arising in the morning. At each follow-up visit, the physician would review the diary card
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and record the most severe rating of daytime and nighttime pain since the previous clinic
visit. Daytime and nighttime UGI pain were rated separately according to the following
scale:
0 = None = I had no pain
1 = Mild = I had some pain, but it didn’t bother me much
2 = Moderate = I had pain that was annoying, but it didn’t interrupt my activities
3 = Severe = I had pain which was so bad I couldn’t do my usual activities
For nighttime pain, activities reflected sleep. The secondary efficacy endpoint was whether
the patient was free of daytime or nighttime pain at weeks 1, 2 or 4.
2.7 Conducting the investigation
When the trial was conducted, there was great pressure to complete it as quickly as possible.
This was due in part to Ranitidine’s rapid gains into the antiulcer market, of which C had
exclusivity for several years. Approximately 60 centers were recruited. The centers were
rigorously and frequently monitored for conformity to protocol and federal regulations, in
an attempt to minimize violations to protocol and collection of questionable if not unusable
data. Roughly half of the sites were monitored by in-house Clinical Monitoring Personnel
(CRA = Clinical Research Associates). The remaining sites were monitored by an outside
Contract Research Organization (CRO).
A fairly heavy advertisement campaign was initiated to recruit possible trial participants. Ads
ran on television and radio and appeared in the print media. In addition circulars were posted
in public areas such as supermarket and laundromat bulletin boards. The ads were targeted to
adults who had been having UGI or ulcer like pain, but who were otherwise healthy.
Weekly meetings were held during the conduct of the trial to monitor progress and deal
with any issues. A proactive approach to clinical data management was taken. Data
collection forms (DCFs) were expressed by each clinic to the data management group (or
picked up by the CRA) where they were rapidly reviewed for completeness, legibility,
entered into the computerized trial database, verified and quality assured. The goal was to
provide a quality assured database for statistical analysis in as short a time as possible after
each patient completed the protocol.
At the time the duodenal ulcer trial was conducted, there was no commercially available 800
mg C tablet. The commercially available 400 mg C tablet was used. Therefore a blood level
trial that demonstrated bioequivalence [Randolph et al, 1986a] between a new 800 mg C
tablet formulation (to be marketed) and two-400 mg C commercially available tablets had to
be conducted with results available by the completion of the duodenal ulcer trial. Results
from these two trials as well as that from specified drug interaction studies provided the
primary data to support filing a supplemental new drug application (SNDA) to the FDA for
the approval of C as a single 800 mg tablet taken at bedtime for the treatment of duodenal
ulcers.
2.8 Statistical analysis methods
2.8.1 Methods
Descriptive and inferential methods were used in presentations and analysis of the trial data
using procedures (PROCS) in the Statistical Analysis System (SAS). Both tables and graphs
reflecting the number of patients, the mean (percent for dichotomous data) and standard
deviation by treatment group and time of assessment were developed.
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Inferential analyses, significance tests and confidence intervals, derived from an analysis of
variance model containing fixed effects of center, strata and treatment group, with contrasts
specified for the pairwise comparisons of interest. P-values for the pairwise comparisons
comprising the primary trial objective were used for statistical inference. Confidence
intervals were used as the basis of inference for secondary trial objectives and for the three
pairwise comparisons not a part of the trial objective.
Since there were many centers and relatively few patients per treatment group per strata per
center were expected, 12 blocks reflecting smoking status (2 levels)-by-baseline ulcer size (6
levels) were defined a priori (Table 2). An analysis of variance model containing the fixed
effects of blocks and treatment was also used to assess the effect of treatment adjusted for
blocks.
Gereralizability (poolability) of treatment effects was assessed by running an analysis of
variance model with block, treatment group and block-by-treatment interaction. In these
analyses the sole interest was the P-value for the interaction term. The blocking factor was
smoking status-by-baseline ulcer size as defined in Table 2. A separate analysis that
included the factors: smoking status, baseline ulcer size, their interaction, and the interaction
of each of these with treatment was also performed.

Table 2. Smoking Status by Ulcer Size (cm) Blocks
Bivariate plots of the proportion of patients with ulcers remaining unhealed and the
proportion of patients with UGI pain (daytime or nighttime) by time of endoscopic
evaluation and treatment group were developed. These plots illustrate the rate of ulcer
healing and pain relief across the times of endoscopic evaluation.
2.8.2 Interim analysis
Prior to finalizing the protocol, we considered including an interim analysis plan.
Incorporating such a plan could result in completing approximately ½ the planned number
of patients. More importantly, it could reduce the time from starting the trial to filing the
SNDA. The idea was accepted initially, but later rejected by upper management; so the final
protocol did not include an interim analysis plan.
However after the trial started, there was a push to conduct an interim analysis. A plan was
developed to conduct an interim (mid-study) analysis after ½ the patients had entered. The
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plan was filed by in-house regulatory affairs personnel with the FDA. Essential features of
the plan ensured preservation of the Type I error and safe guarded blindedness among
investigators, patients, and in-house personnel. We hired an outside consulting group that
generated dummy investigator, patient and treatment group identification. The group also
computed the P-values associated with the 3 pairwise comparisons comprising the study
objectives and reported them to FDA Biometrics and in-house statistical personnel. The trial
was not stopped and ran to completion, eventually enrolling 768 patients. The final results,
based upon more than twice the number of patients in the interim analysis, were similar to
those of the interim analysis in terms of estimates of treatment effects.

3. Results and discussion
3.1 Interim or mid study analysis results
3.1.1 Numbers of patients and baseline characteristics
Table 3 summarizes the number of patients available for the mid-study, interim analysis.
Three hundred and thirty-seven (337) were randomized of which 315 [Peace et al, 1985;
Valenzuela et al, 1985] were considered evaluatable [Peace, 1984] for efficacy for at least one
follow-up visit. The fact that 17 more patients were assigned to the 1600 mg C group
illustrates that slight imbalance across treatment groups can occur in randomized trials
consisting of many centers.
Table 4 contains descriptive results of data available at baseline for mid-study analysis
patients by C treatment group. The treatment groups appear balanced in terms of
demographic characteristics, UGI pain and ulcer size, although the 800 mg C group had
patients with the largest ulcers.
# Randomized
# Evaluatable
Week 1
Week 2
Week 4
≥ 1 week

Total
337

0 mg
76

400 mg
83

800 mg
85

1600 mg
93

304
235
174
315

67
46
41
71

80
63
47
82

73
60
47
75

84
66
39
87

Table 3. Number of Patients by Treatment Group (Mid Study Analysis)
3.1.2 Distribution of patients according to ulcer size
Table 5 provides the distribution of patients at baseline according to ulcer size. Ten percent
(10%) of patients had ulcers of size 0.30 cm; 12.5% had ulcers of size greater than 0.30 but at
most 0.40 cm; 17.8% had ulcers of size greater than 0.40 cm but at most 0.50 cm; 27.2% had
ulcers of size between 0.50 cm and 1.00 cm; 17.8% had ulcers 1.00 cm in size; and 14.7% had
ulcers of size greater than 1.00 cm but at most 3.00 cm.
Table 6 provides the distribution of patients in the Placebo group by baseline ulcer size
whose ulcers had healed by 4 weeks. Seventy-one percent (71%) of Placebo patients with
ulcers of size 0.30 cm healed; 78% of Placebo patients with ulcers of size greater than 0.30
but at most 0.40 cm healed; 45% of Placebo patients with ulcers of size greater than 0.40 cm
but at most 0.50 cm healed; 41% of Placebo patients with ulcers between 0.50 cm and 1.00 cm
in size healed; 30% of Placebo patients with ulcers 1.00 cm in size healed; and 25% of
Placebo patients with ulcers of size greater than 1.00 cm but at most 3.00 cm healed. Table 6
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reflects a strong negative correlation (or trend) between baseline ulcer size and ulcer healing
by 4 weeks; i.e. the smaller the ulcer, the greater is ulcer healing by 4 weeks.
Characteristic

Statistic

0 mg

400 mg

800 mg

1600 mg

Age (yr)

Mean

42

40

44

42

Height (in)

Mean

67

67

67

67

Weight (lb)

Mean

169

160

163

160

Sex

Male (N)

50

62

51

55

Female (N)

26

21

34

38

Caucasian(N)

44

50

58

61

Black (N)

24

21

18

24

Other (N)

8

12

9

8

Day Pain

Mean

2.89

3.13

2.91

2.92

Night Pain

Mean

2.68

2.84

2.80

3.05

Ulcer Size(cm)

Mean

0.76

0.71

0.85

0.75

Smoking

Heavy (N)

40

45

45

48

Light (N)

36

38

40

45

Race

Table 4. Baseline Characteristics (Mid Study Analysis)
Ulcer Size (cm)

% Patients

[0.30]

10.0%

(0.30; 0.40]

12.5%

(0.40; 0.50]

17.8%

(0.50; 1.00)

27.2%

[1.00]

17.8%

(1.00; 3.00]

14.7%

Table 5. Distribution by Ulcer Size - Mid Study Analysis
Ulcer Size (cm)

Healed

[0.30]

71%

(0.30; 0.40]

78%

(0.40; 0.50]

45%

(0.50; 1.00)

41%

[1.00]

30%

(1.00; 3.00]

25%

Table 6. Cumulative 4-week Ulcer Healing Rates: Mid Study Analysis Placebo Patients
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3.1.3 Influence of smoking and ulcer size on ulcer healing
Figure 1 provides a summary of the cumulative proportion of patients across all treatment
groups with healed duodenal ulcers by week of endoscopy and smoking status. Figure 1
reflects a strong negative correlation between smoking status and ulcer healing; i.e. light
smokers have a higher percentage of healed ulcers than do heavy smokers at all weeks of
endoscopy.

Fig. 1. Cumulative Proportion Healed: Light vs Heavy Smokers, Combined Treatment
Groups
1.0

0.9

Ulcer Size (cm)

0.8

0.30
>0 30 ≤ 0
>0.30,
0.40
40

07
0.7

Cu
umulative Proporttion Healed

>0.40, ≤ 0.50
>0.50, ≤ 1.00

0.6

1.00
>1 30 ≤ 3
>1.30,
3.00
00
0.5

0.4

0.3

02
0.2

0.1

0.0
Week 1

Week 2

Week 4

Fig. 2. Cumulative Proportion Healed by Ulcer Size, Combined Treatment Groups
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Figure 2 provides a summary of the cumulative proportion of patients across all treatment
groups with healed duodenal ulcers by week of endoscopy and baseline ulcer size. Figure 2
reflects a strong negative correlation between ulcer size and ulcer healing; i.e. patients with
smaller ulcers have a higher percentage of healed ulcers than do patients with larger ulcers
at all weeks of endoscopy. Note that the categories of ulcer size in Figure 2 are those that
were defined a priori.
The negative correlation between ulcer size and healing is sharpened when collapsing the
six ulcer size categories into three (Figure 3).
1.0

0.9

Ulcer Size (cm)

0.8

>0.30, ≤ 0.50
07
0.7

>0 50 ≤ 1
>0.50,
1.00
00

Cu
umulative Proporttion Healed

>1.00, ≤ 3.00
0.6

0.5

0.4

0.3

02
0.2

0.1

0.0
Week 1

Week 2

Week 4

Fig. 3. Cumulative Proportion Healed by Ulcer Size, Combined Treatment Groups
3.1.4 Cumulative ulcer healing
The cumulative duodenal ulcer healing rates are summarized [Peace et al, 1985; Valenzuela
et al, 1985] in Figure 4 by week of endoscopy and treatment group. The healing rates were:
19%, 18%, 16% and 21% at week 1; 29%, 37%, 38% and 49% at week 2; and 41%, 62%, 72%
and 74%; for the Placebo, 400 mg C, 800 mg C and 1600 mg C groups respectively. At week
4: 800 mg C was effective (P = 0.0002) as compared to Placebo; 800 mg C was marginally
superior to 400 mg C (P = 0.1283); and 1600 mg C provided no clinically significant greater
benefit {δ = 0.0156: 90% CI on ratio of 1600 mg C/ 800 mg C = (0.86; 1.18)} than did 800 mg
C. Even though 800 mg C healed 10% more ulcers than did 400 mg C, the P-value for this
comparison did not achieve statistical significance. Therefore, the mid-study analysis did
not demonstrate that 800 mg C was clinically optimal as formulated in the trial objective.
3.1.5 Generalizability assessment
Table 7 provides a summary of the assessment of generalizability (poolability) of treatment
effect across smoking status, baseline ulcer size and smoking status-by-baseline ulcer size.
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All of the P-values are large and therefore provide no evidence of lack of generalizability of
treatment effects across these subpopulations.
1.0

0.9

Treatment Group

0.8

0 mg
400 mg

07
0.7
Cu
umulative Proporttion Healed

800mg
1600 mg
0.6

0.5

0.4

0.3

02
0.2

0.1

0.0
Week 1

Week 2

Week 4

Fig. 4. Cumulative Proportion of Patients with Healed Ulcers by Week and Treatment
Group
Source

F-value

P-value

Smoke x Size

1.11

0.3559

Smoke x Dose

0.40

0.7518

Size x Dose

1.12

0.3359

Smoke x Size x Dose

0.78

0.7038

Table 7. Assessment of generalizability: Smoking Status by Ulcer Size Subpopulations, Mid
Study Analysis
3.1.6 Complete UGI pain relief and ulcer healing
To illustrate changes in duodenal ulcer healing and complete relief of UGI pain jointly,
bivariate plots (Figure 5 and Figure 6) were generated. To develop these plots, the means
(proportions) of each endpoint were computed by treatment or dose group and each
endoscopy evaluation. The means, corresponding to each endoscopy evaluation and dose
group identification, along with the ranges (0; 1) of each endpoint, were output to a data file.
The data file was accessed by a graphical software package and a plot generated of the mean
pairs by dose group. In generating the plots, the horizontal axis reflects the range of one
endpoint and the vertical axis reflects the range of the other endpoint. In plotting the pairs
of means for each dose group, the endoscopy evaluation corresponding to each pair appears
as a floating index on the graph of each dose group.
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Fig. 5. Proportions of patients with Daytime Pain and Unhealed Ulcers, by Treatment Group
(Mid-Study Analysis)

Fig. 6. Proportions of Patients with and Unhealed Nighttime Pain Ulcers, by Treatment
Group (Mid-Study Analysis)
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In Figures 5 and 6, the horizontal axis reflects the proportion of patients with UGI pain, and
the vertical axis reflects the proportion of patients with unhealed ulcers; rather than
proportions of patients without UGI pain and with healed ulcers. The (1,1) point therefore
reflects where the patients are at baseline, and the (0,0) point reflects the ideal therapeutic
goal of a treatment or dose by the final visit. For a broader discussion of bivariate plots,
references [Peace & Tsai, 2009and Peace & Chen, 2010] may be seen.
Figure 5 is the bivariate plot of daytime UGI pain and lack of ulcer healing. Figure 6 is the
bivariate plot of nighttime UGI pain and lack of ulcer healing. The fact that all dose groups
do not begin at the (1,1) point is due to the fact that some patients had daytime UGI pain but
not nighttime UGI pain and vice versa. Focusing on week 4 results, Figures 5 and 6 reflect a
beautiful picture of dose response, both univariately and bivariately.
3.2 Final study analysis results
At the final study analysis, 168, 182, 165 and 188 patients [Young et al, 1989] were efficacy
evaluatable, in the Placebo, 400 mg C, 800 mg C and 1600 mg C groups, respectively. The
cumulative duodenal ulcer healing rates are summarized in Figure 7 by week of endoscopy
and treatment group. The healing rates were: 17%, 16%, 15% and 21% at week 1; 30%, 40%,
42% and 48% at week 2; and 41%, 62%, 73% and 77%; for the Placebo, 400 mg C, 800 mg C
and 1600 mg C groups respectively. At week 4: 800 mg C was effective (P < 10-8) as
compared to Placebo; 800 mg C was superior to 400 mg C (P = 0.023); and 1600 mg C
provided no clinically significant greater benefit {δ = 0.04: 90% CI on ratio of 1600 mg C/ 800
mg C = (0.96; 1.17)} than did 800 mg C. Therefore, the study demonstrated that 800 mg C
was clinically optimal.
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Group (Final Study Results)
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3.3 Other considerations
3.3.1 Bioequivalence trial of two-400 mg tablets and One-800 mg tablet
At the time the duodenal ulcer trial was conducted, there was no commercially available 800
mg C tablet. The commercially available 400 mg C tablet was used. Therefore a blood level
trial that demonstrated bioequivalence [Randolph et al, 1986a] between a new 800 mg C
tablet formulation (to be marketed) and two-400 mg C commercially available tablets had to
be conducted with results available by the completion of the duodenal ulcer trial.
3.3.2 Cimetidine-by-drug interaction trials
Since C was widely prescribed (the prescription leader at the time), a change in dosage
regimen, particularly a larger dose, required other trials involving the new 800 mg C
regimen. We conducted specific Cimetidine-by-drug interaction trials exploring whether 800
mg C altered the circulating levels of other widely prescribed drugs. The drugs selected
were Theophylline [Seaman et al, 1985; Randolph et al, 1986b; Randolph et al, 1986c] and
Lidocaine [Frank et al, 1983] and Warfarin [Sax, et al, 1987].
3.3.3 Study in the elderly
At the time the duodenal ulcer trial was conducted, the FDA IND/ NDA rewrite was in
progress, which among other specifics, stipulated that pharmaceutical companies should
conduct studies in the elderly to explore whether doses of drugs posed a drug dose-by-age
interaction. In addition, conducting clinical efficacy trials in the elderly was gaining sway.
We actually developed a protocol for a small clinical trial comparing the 800 mg C to
Placebo in elderly (age ≥ 65 years) patients with duodenal ulcers. The trial was to enroll 100
patients balanced across the 800 mg C and Placebo groups.
However, prior to starting the trial the author subset the final database for the trial
described in this chapter and found it contained 101 elderly patients of which 19 were in the
Placebo group and 23 in the 800 mg C group. Randomization in the large trial did not
guarantee balance across treatment groups in this subset of elderly patients. Therefore the
treatment groups were compared statistically in terms of baseline characteristics, and found
to be comparable. Sixteen (16) of 23 (75.6%) elderly patients treated with 800 mg C
experienced ulcer healing, as compared to 6 of 19 (32%) in the Placebo group {δ = 38%; 95%
CI = (10.3%;75.6%)}. Since there was evidence in the original trial database that 800 mg C
was effective in the elderly, there was no need to conduct a separate clinical efficacy trial in
the elderly.
Results from the duodenal ulcer trial, the bioequivalence trial and the Cimetidine-by-drug
interaction trials provided the primary data to support filing a supplemental new drug
application (SNDA) to the FDA for the approval of C as a single 800 mg tablet taken at
bedtime for the treatment of duodenal ulcers.
3.4 Innovative aspects of the clinical trial program
There are several aspects of this program that were rather innovative.
3.4.1 Interim analyses to drop placebo arms
Interim analyses plans that would allow dropping of the placebo arm after establishing
efficacy of the doses, while allowing the dose arms to run to completion for dose
discrimination, were developed.
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3.4.2 Third party blinding during interim analyses
Interim analysis plans that safeguarded company personnel from knowing the identity of
investigators, of patients and treatment groups were developed. These included: a. using an
outside data management group who generated an analysis data set in which dummy
treatment group labels, investigator id and patient id, while preserving the original
randomization appeared; and b. having the outside data management group provide the
blinded data set to the company statistician and to the FDA plus the file containing the IDs
directly to the FDA.
3.4.3 Trial objectives as only three of six pairwise comparisons
The study objective was formulated as only 3 of six pairwise comparisons among the four
dose groups while preserving the overall experiment wise Type I error across these three
comparisons. The other 3 comparisons could be investigated, preferably using confidence
intervals, but they should not invoke a Type I error penalty on the study objective.
3.4.4 Giving up information on center differences
Instead of using centers as a blocking factor in the primary analyses, the 12 classifications of
smoking status-by-baseline ulcer size was used as the blocking factor due to small numbers
of patients per treatment group per center and due to the prognostic importance of smoking
status and baseline ulcer size.
3.4.5 Assessment of type of monitoring by treatment group
An assessment of differences in treatment effect between sites monitored by in-house
personnel and those monitored by the CRO was conducted. There was no treatment-by-type
of monitoring interaction, although the healing rates were generally lower among CRO
monitored sites.
3.4.6 Association between ulcer healing and smoking status and ulcer size
The duodenal ulcer trial definitively established for the first time negative correlations
between ulcer healing and smoking and ulcer healing and baseline ulcer size. Effectiveness
estimates of ulcer healing were adjusted for smoking status and baseline ulcer size.
3.4.7 Utilization of bivariate graphical methods
The duodenal ulcer trial was the first to utilize bivariate plots to profile ulcer healing and
UGI pain relief jointly. The plots illustrated strong dose response in terms of ulcer healing
and UGI pain relief separately and jointly.
3.4.8 Establishing effectiveness based on a subset analysis
Efficacy of the 800 mg C dose was established in the elderly based on a subset analysis. The
trial entered a large enough elderly population to demonstrate that 800mg C was effective in
elderly. That’s a plus for conducting a trial larger than necessary to establish the
effectiveness of each dose.
3.4.9 Maximum use of patients screened with UGI Pain
The focus of this manuscript has been to review features of the land mark, dose comparison
trial of once nightly C in the treatment of duodenal ulcer. This trial was one of three clinical
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trials comprising a major clinical trial program. Each center conducted three protocols: the
one discussed in duodenal ulcer, but also one in gastric ulcer and one in dyspepsia.
Patients were recruited on the basis of having experienced ulcer like symptoms including
epigastric UGI pain. Those who satisfied general entry criteria and who gave consent were
endoscoped. If duodenal ulcer (DU) was confirmed, they entered the DU trial. If gastric
ulcer (GU) was confirmed, they entered a GU trial, and if there was no DU or GU, they
entered a dyspepsia trial. This latter protocol provided a rather stringent definition of
dyspepsia: Ulcer like symptoms including epigastric UGI pain not explained by the
presence of DU or GU. This concurrent protocol method maximized the utility of the
advertisement effort to get patients to the clinic who were experiencing ulcer like symptoms.

4. Conclusions
The SNDA clinical trial program that led to approval of clinically optimal dosing of the first
H2-receptor antagonist: Cimetidine, in the treatment of duodenal ulcers has been reviewed
in detail as a case study. The program included a landmark clinical trial that not only
definitively established 800 mg C hs for 4 weeks as the clinically optimal dosing regimen,
but also was the first to definitively establish negative associations between ulcer healing
and smoking status and ulcer size, as well as the first trial to establish bivariate dose
response in terms of ulcer healing and relief of UGI pain. Clinical optimality of 800 mg C hs
was defined as 800 mg C being effective as compared to placebo; 800 mg C being more
effective than 400 mg C; and 1600 mg C not being more effective than 800 mg C.
In addition, to make maximal use of patients screened, the program included clinical trials
of the 800 mg C regimen in dyspepsia and in gastric ulcers. Further, the program also
included drug interaction trials of the 800 mg C dose with widely used drugs and a
bioequivalence trial of a new 800 mg C tablet compared to two, 400 mg tablets of the
commercially available formulation. The bioequivalence trial was required as the clinical
trial in DU was conducted using the commercially available 400 mg tablet at the time of
study conduct.
Since the development of Cimetidine and other H2-receptor antagonists: Ranitidine (Glaxo),
Famotidine (Merck) and Zinatidine (Lilly), and the proton pump inhibitors (e.g. Prilosec and
Prevacid) more is known about the causes of ulcers in the duodenum and stomach. It is now
widely held that duodenal and gastric ulcers are caused by chronic use of NSAIDS: nonsteroidal, anti-inflammatory medications (that decrease endogenous prostaglandin
production), and by interference with the protective gastric mucosal layer from Helicobacter
pylori infection [Thompson et al, 2010]. Current treatment consists of a combination of two
antibiotics (clarithromycin and either amoxicillin or a nitroimidazole), and a proton pump
inhibitor with the primary aim of eradicating H. Pylori infection [Gisbert et al, 2003].
Bismuth-based regimens are also used for second-line rescue therapy.
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